Wedmont Private Capital Has $352,000 Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Wedmont Private Capital increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN – Get Rating) by 8.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,745 shares of the life sciences company’s stock after acquiring an additional 139 shares during the quarter. Wedmont Private Capital’s holdings in Illumina were worth $352,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of ILMN. Acadian Asset Management LLC increased its position in Illumina by 312.5% during the first quarter. Acadian Asset Management LLC now owns 2,013 shares of the life sciences company’s stock worth $702,000 after acquiring an additional 1,525 shares during the period. Dimensional Fund Advisors LP increased its position in Illumina by 3.1% during the first quarter. Dimensional Fund Advisors LP now owns 237,118 shares of the life sciences company’s stock worth $82,853,000 after acquiring an additional 7,114 shares during the period. Dakota Wealth Management increased its position in Illumina by 13.8% during the first quarter. Dakota Wealth Management now owns 826 shares of the life sciences company’s stock worth $288,000 after acquiring an additional 100 shares during the period. Sequoia Financial Advisors LLC increased its holdings in Illumina by 16.9% in the 1st quarter. Sequoia Financial Advisors LLC now owns 803 shares of the life sciences company’s stock valued at $281,000 after buying an additional 116 shares during the period. Finally, Baird Financial Group Inc. increased its holdings in Illumina by 10.2% in the 1st quarter. Baird Financial Group Inc. now owns 48,943 shares of the life sciences company’s stock valued at $17,108,000 after buying an additional 4,548 shares during the period. 87.97% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on ILMN shares. Canaccord Genuity Group decreased their target price on shares of Illumina from $330.00 to $300.00 and set a “buy” rating on the stock in a report on Tuesday, January 17th. Piper Sandler reissued an “overweight” rating and issued a $290.00 target price on shares of Illumina in a report on Wednesday, February 8th. Barclays decreased their target price on shares of Illumina from $160.00 to $150.00 and set an “underweight” rating on the stock in a report on Wednesday, February 8th. Citigroup lowered shares of Illumina from a “neutral” rating to a “sell” rating and decreased their target price for the company from $200.00 to $180.00 in a report on Monday, December 12th. Finally, Royal Bank of Canada decreased their target price on shares of Illumina from $303.00 to $300.00 and set an “outperform” rating on the stock in a report on Wednesday. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Illumina presently has a consensus rating of “Hold” and a consensus price target of $249.40.

Insider Buying and Selling

In related news, SVP Aimee L. Hoyt sold 3,917 shares of Illumina stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $199.06, for a total transaction of $779,718.02. Following the sale, the senior vice president now directly owns 2,881 shares in the company, valued at approximately $573,491.86. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, SVP Aimee L. Hoyt sold 3,917 shares of the business’s stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $199.06, for a total value of $779,718.02. Following the transaction, the senior vice president now owns 2,881 shares in the company, valued at approximately $573,491.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Alexander Aravanis sold 5,398 shares of the business’s stock in a transaction that occurred on Wednesday, February 22nd. The stock was sold at an average price of $201.74, for a total transaction of $1,088,992.52. Following the completion of the transaction, the senior vice president now owns 2,922 shares in the company, valued at approximately $589,484.28. The disclosure for this sale can be found here. Insiders have sold a total of 11,186 shares of company stock worth $2,255,837 in the last ninety days. Company insiders own 0.13% of the company’s stock.

Illumina Stock Down 0.2 %

NASDAQ:ILMN opened at $224.55 on Friday. The firm’s 50 day simple moving average is $208.86 and its 200 day simple moving average is $208.73. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.28 and a quick ratio of 1.08. Illumina, Inc. has a one year low of $173.45 and a one year high of $371.16. The company has a market cap of $35.48 billion, a PE ratio of -8.02, a P/E/G ratio of 8.32 and a beta of 1.15.

Illumina (NASDAQ:ILMN – Get Rating) last posted its earnings results on Tuesday, February 7th. The life sciences company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.11). Illumina had a positive return on equity of 3.79% and a negative net margin of 96.12%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the business earned $0.75 earnings per share. The firm’s quarterly revenue was down 9.2% on a year-over-year basis. On average, research analysts anticipate that Illumina, Inc. will post 1.41 earnings per share for the current year.

Illumina Profile

(Get Rating)

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.